Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative ≤ T1b Breast Cancer
Prior to the advent of Oncotype DX 21-gene recurrence score (oDX) assay, the National Comprehensive Cancer Network (NCCN) guideline supported omission of adjuvant chemotherapy in patients with ≤ 1 cm (T1b) hormone receptor-positive (HR +), human epidermal growth factor receptor 2 (HER2−) node tumors. However, around 30% of these patients would have an oDX recurrence score that warrants consideration of adjuvant chemotherapy. To clarify the potential benefit of oDX in these patients, we performed a retrospective analysis comparing clinical outcomes of women with T1a or T1b, N0 HR + HER2− according to performance of oDX.
Patients and Methods
After receiving institutional review board (IRB) approval, an institutional database was queried to identify patients with HR + HER2− ≤ T1bN0 tumors (n = 2307) diagnosed between 2009 and 2018. Patients were further stratified by recurrence score (RS) defined as low (< 18), intermediate (18–30), or high (> 30). Log-rank, Kaplan–Meier, and inverse probability of treatment weighting (IPW) analyses were used to compare disease-free survival (DFS) and overall survival (OS) across groups.
Performance of oDX (n = 1149, 49.8%) was associated with larger tumors, younger age, and White race. On univariate analysis, performance of oDX was associated with improved OS (P < 0.01). On multivariate IPW analysis, performance of oDX lengthened DFS by an average of 16.5 months, while OS was similar between groups (P < 0.01 and P = 0.73). The improved DFS was mainly driven by those with tumors ≥ T1b.
Overall, outcomes were excellent regardless of oDX testing. Performance of oDX testing was associated with improved DFS in patients with tumors ≥ T1b. Our results support routine use of oDX testing in patients with tumors ≥ T1b.
Authors have no financial relationships or conflicts of interest relevant to this article to disclose.
- 6.6. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65. https://doi.org/10.1016/s1470-2045(09)70314-6 CrossRefPubMedGoogle Scholar
- 8.8. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol. 2010;28(11):1829–1834. https://doi.org/10.1200/jco.2009.24.4798 CrossRefPubMedGoogle Scholar
- 9.9. Gluz O, Nitz UA, Christgen M, et al. West German Study Group Phase III PlanB Trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34(20):2341–2349. https://doi.org/10.1200/jco.2015.63.5383 CrossRefPubMedGoogle Scholar
- 10.Wang M, Wu K, Ding A, Chen H, Zhang M, Chen H. The prognostic significance of the oncotype dx recurrence score in T1-2N1M0 estrogen receptor-positive HER2-negative breast cancer based on the prognostic stage in the updated AJCC 8th edition. Ann Surg Oncol. 2018:2–10. https://doi.org/10.1245/s10434-018-7068-3 CrossRefGoogle Scholar
- 13.13. Williams AD, Reyes SA, Arlow RL, Tchou J, De La Cruz LM. Is age trumping genetic profiling in clinical practice? relationship of chemotherapy recommendation and Oncotype DX recurrence score in patients aged < 50 years versus ≥ 50 years, and trends over time. Ann Surg Oncol. 2018. https://doi.org/10.1245/s10434-018-6600-9 CrossRefPubMedGoogle Scholar
- 14.U.S. Census Bureau. american community survey design and methodology. 2014;(January). https://www.census.gov/data/developers/data-sets.html.
- 17.17. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. https://doi.org/10.1002/sim.6607 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.22. Chen C, Dhanda R, Forsyth M, Tseng W-Y, Patt DA. Evaluating use characteristics for the Onco type DX 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. J Oncol Pract. 2013;9(4):182–187. https://doi.org/10.1200/jop.2012.000638 CrossRefPubMedPubMedCentralGoogle Scholar